



Factor XIII Prior Authorization

Drug(s) Applied: Corifact, Tretten

Criteria:

Drug(s) Applied will be approved when the requested medication is being used for an FDA approved indication and all of the following criteria are met:

- I. Initial Approval Criteria
 - A. Factor XIII deficiency (Congenital or A-Subunit deficiency) as indicated by chart notes within past 90 days
 - 1. Requested agent is being used for ONE of the following:
 - a) On-demand use for bleeds or
 - b) Peri-operative management of bleeding or
 - c) Prophylaxis and
 - 2. Prescriber is a specialist or has consulted with a specialist in the area of the patient's diagnosis (e.g., hematology)

Approval Duration: 12 Months

- II. Continued Therapy Approval
 - A. Factor XIII deficiency (Congenital or A-Subunit deficiency) as indicated by chart notes within past 12 months
 - 1. Patient has been previously approved for the requested agent through the plan's Prior Authorization process or meets the initial therapy criteria above **and**
 - 2. Patient has been treated with the requested agent (starting on samples is not approvable) within the past 90 days **and**
 - 3. Patient has shown clinical benefit since starting the requested agent (i.e., less breakthrough bleeds) **and**
 - 4. Prescriber is a specialist or has consulted with a specialist in the area of the patient's diagnosis (e.g., hematology)

Approval Duration: 12 months

Policy Owned by: Curative PBM team